tiprankstipranks
Ovid Therapeutics Inc (OVID)
NASDAQ:OVID
Holding OVID?
Track your performance easily

Ovid Therapeutics (OVID) Income Statement

1,291 Followers

Ovid Therapeutics Income Statement

Last quarter (Q3 2024), Ovid Therapeutics's total revenue was $173.00K, an increase of 58.76% from the same quarter last year. In Q3, Ovid Therapeutics's net income was $-14.01M. See Ovid Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 631.56K$ 391.69K$ 1.50M$ 208.38M$ 12.62M-
Cost of Revenue
------
Gross Profit
$ 631.56K$ 391.69K$ 1.50M$ 208.38M$ 12.62M-
Operating Expense
$ 69.98M$ 59.67M$ 57.05M$ 84.17M$ 94.05M$ 60.46M
Operating Income
$ -69.35M$ -59.28M$ -55.55M$ 124.21M$ -81.43M$ -60.46M
Net Non Operating Interest Income Expense
$ -4.90M$ -4.90M---$ 948.22K
Other Income Expense
$ -27.90M$ 2.00M$ 1.38M$ 45.69K--
Pretax Income
$ -32.50M$ -52.34M$ -54.17M$ 124.16M$ -81.04M$ -60.46M
Tax Provision
---$ 1.33M--
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -32.65M$ -52.34M$ -54.17M$ 119.84M$ -81.04M$ -60.46M
Basic EPS
$ -0.46$ -0.74$ -0.77$ 1.78$ -1.39-
Diluted EPS
$ -0.46$ -0.74$ -0.77$ 1.76$ -1.39$ -1.54
Basic Average Shares
$ 283.29M$ 70.58M$ 70.42M$ 67.48M$ 58.45M$ 39.22M
Diluted Average Shares
$ 283.57M$ 70.58M$ 70.42M$ 68.07M-$ 39.22M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 69.98M$ 59.67M$ 57.05M$ 84.17M$ 94.05M$ 60.46M
Net Income From Continuing And Discontinued Operation
$ -32.50M$ -52.34M$ -54.17M$ 122.83M$ -81.04M$ -60.46M
Normalized Income
$ -29.11M$ -41.35M-$ 98.09M--
Interest Expense
------
EBIT
$ -64.41M$ -59.28M$ -55.55M$ 124.21M$ -81.43M$ -60.46M
EBITDA
$ -63.16M$ -57.69M$ -54.17M$ 124.45M$ -81.12M$ -60.21M
Currency in USD

Ovid Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis